Joint Clinical Trials Office

You are here

A Phase 1 Study of LY3200882 in Patients with Solid Tumors

Clinical Trial Details

This clinical trial is for men and women with high-grade gliomas that has recurred for the first time. There is currently a need for more effective treatment methods for this disease. 

The purpose of this study is to help answer the following research questions: 

  • How much LY3200882 should be given to patients with advanced cancer? 
  • The safety of LY3200882 and any side effects you might have when you take it. 

The study drug (LY3200882) will be administered orally (taken by mouth). You will receive a repeating cycle of either 14 days of treatment followed by 14 days with no treatment, or 21 days of treatment followed by 7 days with no treatment. You have a 1 in 2 chance of getting either the 2 week or 3 week treatment. Your treatment will stop when your disease progresses, you cannot tolerate the treatment, or you or your study doctor wishes to stop treatment. 

The duration of your participation depends on how well your disease responds to the study treatment. 

Key Eligibility: 
  • Open to men and women above the age of 18 who have been diagnosed with high-grade gliomas 
  • Histologically confirmed diagnosis of IDH-mutant high-grade (III or IV) glioma 
  • First recurrence of glioma 
  • Detailed eligibility will be reviewed when you contact the study team 

Contact

Monique Tarrant, RN, MSN, MPH
mot2013@med.cornell.edu
(212) 746-4154

Primary Investigator

Howard A. Fine, MD

Protocol ID(s)

Weill Cornell Medicine IRB #:

1702017959

ClinicalTrials.gov:

NCT02937272

Status:

Open to Enrollment

Age Group

Adult

Sponsor

Drug/Device

Drug

Study Type

Phase

1